^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Gastric Cancer
    Drug:zanidatamab zovodotin (ZW49) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

    Excerpt:
    ...- Pathologically-confirmed diagnosis of breast cancer, gastroesophageal adenocarcinoma (GEA), or other HER2-expressing cancer with evidence of locally advanced (unresectable) and/or metastatic disease....
    Trial ID:
    NCT03821233
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer

    Published date:
    04/04/2023
    Excerpt:
    Anti-tumor activity was observed in 5/7 (71%) PDX models of gastric cancer after a single i.v. dose of 6 mg/kg, including in models with moderate and weak HER2 expression....The strong anti-tumor activity of ZW-49 in vivo, together with its ability to induce ICD and potential adaptive immune responses, support ZW49 as a promising ADC for the treatment of HER2-expressing cancers...
    DOI:
    https://doi.org/10.1158/1538-7445.AM2023-2633